Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 537-546

  Mansour, Mahmoud ^a   Schwartz, Dean ^a   Judd, Robert ^a   Akingbemi, Benson ^a   Braden, Tim ^a   Morrison, Edward ^a   Dennis, John ^a   Bartol, Frank ^a   Hazi, Amanda ^a   Napier, India ^a   Abdel Mageed, Asim B ^b  

^a AUBURN UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fasn inhibitors; Fatty acid synthase; Peroxisome proliferator activated receptor ; Prostate cancer; Thiazolidinediones

Indexed keywords

ACETYL CO A CARBOXYLASE 1; CARBOXYLASE; CERULENIN; FATTY ACID SYNTHASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL LINE; CELL VIABILITY; DRUG MECHANISM; IC 50; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION;

ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; CHROMANS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID SYNTHETASE COMPLEX, TYPE I; HUMANS; HYPOGLYCEMIC AGENTS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PPAR GAMMA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED; VASODILATOR AGENTS;

EID: 78651234318     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.877     Document Type: Article

References (43)

1. Woolf SH: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 333: 1401-1405, 1995.
2. Shiau CW, Yang CC, Kulp SK, et al: Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 65: 1561-1569, 2005.
3. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S and Koeffler HP: Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60: 5494-5498, 2000.
4. Yang CC, Wang YC, Wei S, et al: Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. Cancer Res 67: 3229-3238, 2007.
5. Wei S, Lin LF, Yang CC, et al: Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma. Mol Pharmacol 72: 725-733, 2007.
6. Mueller E, Smith M, Sarraf P, et al: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97: 10990-10995, 2000.
7. Hatton JL and Yee LD: Clinical use of PPARgamma ligands in cancer. PPAR Res 2008: 159415, 2008.
8. Karayi MK and Markham AF: Molecular biology of prostate cancer. Prostate Cancer Prostatic Dis 7: 6-20, 2004.
9. Lee SY, Hur GY, Jung KH, et al: PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 51: 297-301, 2006.
10. Girnun GD, Naseri E, Vafai SB, et al: Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11: 395-406, 2007.
11. Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9: 1-9, 2003.
12. Lee CH, Olson P and Evans RM: Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144: 2201-2207, 2003.
13. Chaffer CL, Thomas DM, Thompson EW and Williams ED: PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 6: 53, 2006.
14. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL and Townsend CA: Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97: 3450-3454, 2000.
15. Pflug BR, Pecher SM, Brink AW, Nelson JB and Foster BA: Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate 57: 245-254, 2003.
16. Menendez JA, Colomer R and Lupu R: Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells. Oncol Rep 12: 411-422, 2004.
17. Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351: 1488-1490, 2004.
18. Mashima T, Seimiya H and Tsuruo T: De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 100: 1369-1372, 2009.
19. Epstein JI, Carmichael M and Partin AW: OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45: 81-86, 1995.
20. Kuhajda FP: Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66: 5977-5980, 2006.
21. Swinnen JV, Roskams T, Joniau S, et al: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98: 19-22, 2002.
22. Shurbaji MS, Kalbfleisch JH and Thurmond TS: Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 27: 917-921, 1996.
23. Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000.
24. Wakil SJ: Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28: 4523-4530, 1989.
25. Migita T, Ruiz S, Fornari A, et al: Fatty acid synthase: A metabolicenzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 101: 519-532, 2009.
26. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G and Swinnen JV: RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63: 3799-3804, 2003.
27. Pizer ES, Chrest FJ, DiGiuseppe JA and Han WF: Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 58: 4611-4615, 1998.
28. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE and Kuhajda FP: Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56: 2745-2747, 1996.
29. Liu B, Wang Y, Fillgrove KL and Anderson VE: Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother Pharmacol 49: 187-193, 2002.
30. Loftus TM, Jaworsky DE, Frehywot GL, et al: Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288: 2379-2381, 2000.
31. Mansour M, Coleman E, Dennis J, et al: Activation of PPARgamma by rosiglitazone does not negatively impact male sex steroid hormones in diabetic rats. PPAR Res 2009: 101857, 2009.
32. Vandesompele J, De Preter K, Pattyn F, et al: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: Research0034, 2002.
33. Watkins SM, Reifsnyder PR, Pan HJ, German JB and Leiter EH: Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J Lipid Res 43: 1809-1817, 2002.
34. Baron A, Migita T, Tang D and Loda M: Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 91: 47-53, 2004.
35. Wei S, Yang J, Lee SL, Kulp SK and Chen CS: PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett 276: 119-124, 2009.
36. Neuschwander-Tetri BA, Isley WL, Oki JC, et al: Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 129: 38-41, 1998.
37. Lupu R and Menendez JA: Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Endocrinology 147: 4056-4066, 2006.
38. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G and Swinnen JV: Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 15: 1817-1828, 2001.
39. Dehm SM and Tindall DJ: Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99: 333-344, 2006.
40. Swinnen JV, Heemers H, van de Sande T, et al: Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 92: 273-279, 2004.
41. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997.
42. Bertram J, Peacock JW, Tan C, et al: Inhibition of the phosphatidylinositol 3′-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Cancer Res 66: 4781-4788, 2006.
43. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.